
FAQs: Medical and surgical management of LUTS/BPH under the 2026 AUA guideline
These FAQs outline key AUA guideline recommendations on the medical and surgical management of LUTS secondary to BPH.
On May 7, 2026, the American Urological Association (AUA) released its 2026 Management of Lower Urinary Tract Symptoms (LUTS) Attributed to
“This updated guideline provides clinicians with clear, practical recommendations to help ensure patients receive the most appropriate evaluation and treatment based on the best available evidence,” said Ramy Goueli, MD, MHS, chair of the guideline, in a news release from the AUA.3 The guideline emphasizes shared decision-making and individualized care, “recognizing that urinary symptoms may result from multiple contributing factors beyond prostate enlargement alone,” the AUA noted.3
The following FAQs summarize the key recommendations on medical and surgical management; a companion FAQ covers the
1. What principles guide non-procedural management?
Part II notes that non-procedural interventions should be provided within the shared decision-making context and should take into account efficacy as well as durability and adverse events. It also notes the importance of disclosing unique actions of medication to relevant patient populations, such as patients on active surveillance for prostate cancer, and addresses specific risks for populations such as patients undergoing ophthalmologic surgery. Consistent with these principles, clinicians should provide behavioral/lifestyle interventions before or in addition to initiating pharmacologic treatment (Moderate Recommendation; Evidence Level: Grade B).
2. Which alpha blockers are recommended, and how should clinicians choose among them?
Clinicians should offer 1 of 3 uroselective alpha blockers (ABs): alfuzosin, silodosin, or tamsulosin (Strong Recommendation; Evidence Level: Grade A). Patients should be told that symptomatic improvements are similar among all ABs, so clinicians should counsel patients on the agents’ different adverse effect profiles and make a selection based on patient preference and comorbidities (Clinical Principle). Patients planning cataract surgery should be counseled about the risks of intraoperative floppy iris syndrome with ABs and advised to discuss these risks with their ophthalmologist (Clinical Principle).
3. What roles do tadalafil and 5-alpha reductase inhibitors play?
Clinicians should offer daily 5-mg tadalafil for patients with LUTS/BPH with or without erectile dysfunction (ED) (Moderate Recommendation; Evidence Level: Grade B). In patients with an estimated prostate volume greater than 30 cc and/or a prostate-specific antigen (PSA) level greater than 1.5 ng/mL, clinicians should offer a 5-alpha reductase inhibitor (5-ARI) for symptom relief (Moderate Recommendation; Evidence Level: Grade A) and to reduce the risk of clinical BPH progression, such as worsening symptoms, acute urinary retention (AUR), or need for BPH surgery (Clinical Principle). A 5-ARI may also be offered for persistent prostate-related hematuria due to LUTS/BPH (Expert Opinion).
When prescribing 5-ARIs, clinicians should counsel patients about the risks of adverse effects and the impact on prostate cancer diagnosis (Moderate Recommendation; Evidence Level: Grade C). Patients on active surveillance for prostate cancer should be counseled that 5-ARI treatment is unlikely to increase the risk of prostate cancer progression (Expert Opinion).
4. Which combination therapies are recommended, including for storage symptoms?
In patients who meet the prostate volume and/or PSA threshold, clinicians should offer a 5-ARI in combination with an AB (Moderate Recommendation; Evidence Level: Grade B). Combinations that include tadalafil carry weaker recommendations: clinicians may offer daily 5-mg tadalafil with a uroselective AB in patients with or without ED, or with a 5-ARI in patients who meet the volume and/or PSA threshold (Conditional Recommendation; Evidence Level: Grade C for each).
In patients with moderate to severe predominant storage LUTS, clinicians may offer anticholinergic agents or beta-3 agonists, either alone or in combination with an AB (Conditional Recommendation; Evidence Level: Grade C for each). If storage LUTS persist despite pharmacologic treatment, clinicians should add behavioral/lifestyle interventions (Expert Opinion).
5. When should patients move from medical to procedural therapy?
Clinicians should offer procedural therapies to patients who have renal insufficiency secondary to BPH, refractory urinary retention secondary to BPH, recurrent urinary tract infections, recurrent bladder stones or gross hematuria due to BPH, and/or LUTS/BPH refractory to other therapies, as well as to patients unwilling to use other therapies (Clinical Principle). A procedure should not be performed solely for the presence of an asymptomatic bladder diverticulum, although evaluation for bladder outlet obstruction should be considered (Clinical Principle). For patients who do not experience symptom improvement with treatment, clinicians should pursue an alternative diagnosis and/or recommend an alternative treatment pathway (Clinical Principle).
6. What counseling should precede a BPH procedure?
Clinicians should counsel patients about the progressive bladder functional changes associated with LUTS/BPH to inform procedural timing and selection (Expert Opinion) and should educate patients on potential changes in orgasmic, erectile, and ejaculatory function associated with procedural intervention (Clinical Principle). Clinicians should also discuss known relative BPH-specific retreatment rates (Moderate Recommendation; Evidence Level: Grade B). For patients pursuing ejaculation-sparing procedures, clinicians should discuss that the tissue-preserving nature of these technologies increases the risk of BPH-specific retreatment (Expert Opinion).
7. Which resective, enucleation, and vaporization procedures are recommended?
Clinicians should offer bipolar or monopolar transurethral resection of the prostate (TURP) (Strong Recommendation; Evidence Level: Grade A) and laser enucleation of the prostate, including holmium laser enucleation of the prostate (HoLEP) and thulium laser enucleation of the prostate (ThuLEP) (Strong Recommendation; Evidence Level: Grade A). Clinicians should also offer photoselective vaporization of the prostate (PVP) (Strong Recommendation; Evidence Level: Grade B) and may offer bipolar transurethral vaporization of the prostate (Clinical Principle) or alternative transurethral enucleation techniques (Conditional Recommendation; Evidence Level: Grade C).
Two options are tied to prostate size at opposite ends of the spectrum. Transurethral incision of the prostate (TUIP) may be offered for prostates smaller than 30 cc without a median lobe (Clinical Principle), whereas simple prostatectomy with an open, laparoscopic, or robotic approach should be offered for prostates larger than 80 cc (Moderate Recommendation; Evidence Level: Grade B).
8. Which minimally invasive options are recommended for prostates 30 to 80 cc?
For prostates 30 to 80 cc, clinicians should offer water vapor thermal therapy and robotic waterjet treatment (RWT), as well as prostatic urethral lift (PUL) in patients without an obstructing median lobe (Moderate Recommendation; Evidence Level: Grade B for each). RWT may also be offered for prostates 80 to 150 cc (Expert Opinion). Before proceeding with PUL, clinicians should counsel patients that the procedure involves implanting permanent tines that may affect future procedures and future imaging of the prostate (Expert Opinion).
9. Where do newer devices and prostate artery embolization fit?
A temporary implantable prostate device (TIPD) may be offered for prostates 25 to 75 cc without an obstructing median lobe (Expert Opinion), and an intraprostatic drug-coated balloon may be offered for prostates 20 to 80 cc with a prostatic urethral length of 32 to 55 mm and no obstructing median lobe (Conditional Recommendation; Evidence Level: Grade C). Prostate artery embolization (PAE) with particle embolics may be offered for prostates 50 cc or larger (Conditional Recommendation; Evidence Level: Grade B).
Urologists should assess patients considering PAE before the procedure, and PAE should be performed by interventional radiologists specifically trained in the technique (Expert Opinion for each). Patients should also be counseled that PAE exposes them to radiation (Clinical Principle). Clinicians should not offer high-intensity focused ultrasound ablation/cavitation or cryoablation for LUTS/BPH outside the context of a clinical trial (Expert Opinion).
10. How should urinary retention and primary bladder neck obstruction be managed?
For patients with AUR related to LUTS/BPH, clinicians should optimize modifiable risk factors and prescribe a uroselective AB to be taken for at least 3 days before a voiding trial (Clinical Principle). Patients who pass a trial without catheter should be informed that they remain at increased risk for recurrent urinary retention (Clinical Principle). In patients with catheter-dependent urinary retention, clinicians should recommend resective technologies, taking patient comorbidities into consideration (Expert Opinion).
In patients with suspected primary bladder neck obstruction, clinicians may offer TUIP, transurethral resection of the bladder neck, or TIPD (Expert Opinion).
11. What options are available for medically complicated patients and those on active surveillance?
For patients who are at high risk of bleeding or who require anticoagulant/antiplatelet medications during BPH procedures, clinicians may offer HoLEP, ThuLEP, PVP, or PAE (Expert Opinion). Clinicians may also offer procedural BPH treatment to patients with LUTS/BPH who are on active surveillance for prostate cancer (Expert Opinion).
12. How should patients be followed after treatment?
After initiating medical therapy, clinicians should evaluate patients within 6 months to assess response, using standardized symptom scores and an evaluation of any adverse events (Clinical Principle). After a BPH procedure, clinicians should evaluate patients for at least 1 year to assess response; re-evaluation should include standardized symptom scores and assessment of adverse events, and clinicians may assess post-void residual and uroflowmetry (Clinical Principle).
_____
REFERENCES
1. Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management. J Urol. 0(0). doi:10.1097/JU.0000000000005098
2. Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part III: Procedural/Surgical Management. J Urol. 0(0). doi:10.1097/JU.0000000000005099
3. American Urological Association Releases the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Guideline. News release. American Urological Association. May 7, 2026. Accessed May 18, 2026.
Related to this article








